Literature DB >> 30001785

A Review of Osteoporosis in the Older Adult: An Update.

Paloma Alejandro1, Florina Constantinescu2.   

Abstract

Osteoporosis in the elderly population is common. It results in more than 1.5 million fractures per year in the United States. The goal of managing osteoporosis is to prevent fractures. In men, osteoporosis is underrecognized and undertreated. More men than women die every year as a consequence of hip fractures. Bisphosphonates are the first-line treatment of men and women. In the past several years, advances in bone biology have resulted in major therapeutic advances. A review of diagnosis and treatment of osteoporosis is described.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bisphosphonates; DXA; Drug holiday; Elderly; FRAX; Hip fractures; Osteoporosis

Mesh:

Substances:

Year:  2018        PMID: 30001785     DOI: 10.1016/j.rdc.2018.03.004

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  22 in total

Review 1.  Nanodelivery of phytobioactive compounds for treating aging-associated disorders.

Authors:  Oleh Lushchak; Olha Strilbytska; Alexander Koliada; Alina Zayachkivska; Nadia Burdyliuk; Ihor Yurkevych; Kenneth B Storey; Alexander Vaiserman
Journal:  Geroscience       Date:  2019-11-04       Impact factor: 7.713

2.  Differences in geometric strength at the contralateral hip between men with hip fracture and non-fractured comparators.

Authors:  Alan M Rathbun; Jay Magaziner; Michelle D Shardell; Thomas J Beck; Laura M Yerges-Armstrong; Denise Orwig; Gregory E Hicks; Alice S Ryan; Marc C Hochberg
Journal:  Bone       Date:  2019-12-05       Impact factor: 4.398

3.  A nomogram for short-term recurrent pain after percutaneous vertebroplasty for osteoporotic vertebral compression fractures.

Authors:  Z Liu; X Zhang; H Liu; D Wang
Journal:  Osteoporos Int       Date:  2021-11-11       Impact factor: 4.507

4.  Exploring the relationship between osteoporosis and polycystic ovary syndrome based on bioinformatics.

Authors:  Chun-Xiao Dang; Ding Wang; Xiao Yu; Peng-Fei Liu; Jin-Xing Liu
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

5.  One Novel Phantom-Less Quantitative Computed Tomography System for Auto-Diagnosis of Osteoporosis Utilizes Low-Dose Chest Computed Tomography Obtained for COVID-19 Screening.

Authors:  Tang Xiongfeng; Zhang Cheng; He Meng; Ma Chi; Guo Deming; Qi Huan; Chen Bo; Yang Kedi; Shen Xianyue; Wong Tak-Man; Lu William Weijia; Qin Yanguo
Journal:  Front Bioeng Biotechnol       Date:  2022-06-28

6.  Targeted next generation sequencing of nine osteoporosis-related genes in the Wnt signaling pathway among Chinese postmenopausal women.

Authors:  Can Li; Qin Huang; Rui Yang; Xiaodong Guo; Yu Dai; Junchao Zeng; Yun Zeng; Lailin Tao; Xiaolong Li; Haolong Zhou; Qi Wang
Journal:  Endocrine       Date:  2020-03-08       Impact factor: 3.633

7.  Serum C-C Motif Ligand 11/eotaxin-1 May Serve as a Candidate Biomarker for Postmenopausal Osteoporosis.

Authors:  Wen Wang; Ci-You Huang; Zhuo-Ping Wang; Shan-Shan Xu; Tie-Yong Qian; Yi-Ding Chen; Wei-Guo Wu
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

8.  Iron-Chelating Agent Can Maintain Bone Homeostasis Disrupted by Iron Overload by Upregulating Wnt/Beta-Catenin Signaling.

Authors:  Wei Xu; Ronghua Yu; Xiaodong Zhu; Zhikun Li; Jianjun Jia; Dachuan Li; Yu Chen; Xiangyang Zhang
Journal:  Biomed Res Int       Date:  2020-05-24       Impact factor: 3.411

9.  Association between renal function and bone mineral density in healthy postmenopausal Chinese women.

Authors:  Shuang Li; Junkun Zhan; Yanjiao Wang; Yi Wang; Jieyu He; Wu Huang; Zhifeng Sheng; Youshuo Liu
Journal:  BMC Endocr Disord       Date:  2019-12-26       Impact factor: 2.763

10.  Commentary: Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD.

Authors:  Carmen Mannucci; Gioacchino Calapai; Sebastiano Gangemi
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.